TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04147195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006
Description: 5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor
Description: 100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
Study: NCT00739115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox gas
Description: Heliox gas used in conjunction with nasal CPAP
Study: NCT02474849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study: NCT00930956

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 30 g of carbohydrate per Arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: 30 g of carbohydrate per Arm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: 30 g of carbohydrate per Arm
Study: NCT04350931

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
Study: NCT04627558

Intervention type: OTHER
Intervention: stroke patients, balance assessment
Description: validity relability dubousset functional test
Study: NCT04295369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
Study: NCT01335906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
Study: NCT04794673

Intervention type: OTHER
Intervention: brain damage
Description: Have or not have the brain damage and the location of the damage
Study: NCT01718951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: golimumab
Description: golimumab
Study: NCT04794673

Intervention type: OTHER
Intervention: brain damage
Description: Have or not have the brain damage and the location of the damage

Intervention type: OTHER
Intervention: brain damage
Description: Have or not have the brain damage and the location of the damage
Study: NCT02932605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol
Study: NCT02004314

Intervention type: DRUG
Group type: OTHER
Intervention: Chloroquine
Study: NCT01711008

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No breakfast
Study: NCT04406116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave coagulation using HS1 Instrument
Description: Microwave therapy at 5.8 GHz
Study: NCT02462109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.
Study: NCT02799888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (in HLA-Unrelated Donor Transplantation)
Description: Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (in HLA-Mismatched Related Donor Transplantation)
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
Study: NCT04728984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalfurafine Hydrochloride
Description: Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalfurafine Hydrochloride+Placebo
Description: Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
Study: NCT03571724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Menthol Very Low Nicotine Cigarettes
Description: King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Very Low Nicotine Cigarettes
Description: King size menthol cigarettes containing 0.4mg nicotine /g tobacco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject's UB non-mentholated filtered cigarettes
Description: King size non-menthol cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject's UB mentholated filtered cigarettes
Description: King size menthol cigarettes
Study: NCT01718951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: pamidronate
Study: NCT01699737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Encapsulated Glimepiride tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for comparator
Study: NCT01921361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Intrathecal 3ml (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Intrathecal 3ml (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Intrathecal 3ml (15 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intrathecal 3 microgram (diluted 1/10, 0.3 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
Study: NCT03065933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended-release clonidine
Description: Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
Study: NCT00119561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Support
Description: Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
Study: NCT01993771

Intervention type: PROCEDURE
Intervention: Surgery with general anaesthesia.

Intervention type: PROCEDURE
Intervention: Raw EEG
Study: NCT03061058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intraperitoneal and/or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intraperitoneal and/or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intraperitoneal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intraperitoneal and/or intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intraperitoneal and/or intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: oral
Study: NCT04334447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved primary care HF diagnostics
Description: Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
Study: NCT01609088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythritol-containing beverage
Description: Orange flavored beverage containing erythritol
Study: NCT02259686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 1mg subcutaneous
Description: single subcutaneous injection of Apelin 1mg subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 1mg intravenous
Description: 15 minute intravenous bolus of Apelin 1mg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 5mg subcutaneous
Description: single subcutaneous injection of Apelin 5mg subcutaneous
Study: NCT04334447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure education
Description: Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
Study: NCT02259686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 5mg intravenous
Description: 15 minute intravenous infusion of Apelin 5mg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin 10 mg subcutaneous
Description: 24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
Study: NCT01606306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
Study: NCT04334447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured transitional protocol planning post-discharge care
Description: Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
Study: NCT01606306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: as-needed fluticasone propionate
Description: Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
Study: NCT03528408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
Study: NCT00116935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: imatinib 400 mg/day orally qd for 12 months
Study: NCT00277368

Intervention type: OTHER
Intervention: A structured questionnaire for seizure-related headache
Description: A structured questionnaire for seizure-related headache
Study: NCT00116935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: imatinib 400 mg/d orally qd for 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: imatinib 400 mg/d orally qd for 36 months
Study: NCT04665674

Intervention type: OTHER
Intervention: Standard of care
Description: Standard of car of pulmonary Langerhans cell histiocytosis (PLCH)
Study: NCT04656977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: The proposed intervention will consist in three weekly sessions of 2h focused, respectively, on: (1) gathering information about the loss and psychoeducation about perinatal grief, and introduction to the virtual environment; (2) through the use of the virtual environment, women will be assisted in the elaboration and acceptation of loss; (3) recreate, using the features of the virtual environment (i.e., a series of different virtual landscapes and symbolic elements personalized to each participant as personal pictures, sounds or videos) a new and positive metaphor representing the woman's future life.
Study: NCT02859064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Y-90 microspheres
Description: To be administered by injection through a trans-femoral catheter into the hepatic artery.
Study: NCT02665585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting procedure by carotid stent implantation
Description: Carotid stenting procedure by carotid stent implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting procedure by carotid stent implantation
Description: Carotid stenting procedure by carotid stent implantation
Study: NCT04656977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: The TAU condition is a homogenous standard program proposed by the CERIF at UQO based on group counseling offered to women and men who experienced a perinatal loss.
Study: NCT04102020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous (SC) or intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Oral Tablet
Study: NCT01547195

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: swim training
Description: Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training walk
Description: The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes.
Study: NCT00125359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib and bexarotene
Description: Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.